325 related articles for article (PubMed ID: 30248593)
1. Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.
Gasim M; Bernstein CN; Graff LA; Patten SB; El-Gabalawy R; Sareen J; Bolton JM; Marriott JJ; Fisk JD; Marrie RA;
Mult Scler Relat Disord; 2018 Nov; 26():124-156. PubMed ID: 30248593
[TBL] [Abstract][Full Text] [Related]
2. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
4. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
5. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
[TBL] [Abstract][Full Text] [Related]
6. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis.
Dolladille C; Chrétien B; Peyro-Saint-Paul L; Alexandre J; Dejardin O; Fedrizzi S; Defer G
Neurotherapeutics; 2021 Jul; 18(3):1657-1664. PubMed ID: 34231126
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis.
Fiest KM; Walker JR; Bernstein CN; Graff LA; Zarychanski R; Abou-Setta AM; Patten SB; Sareen J; Bolton JM; Marriott JJ; Fisk JD; Singer A; Marrie RA;
Mult Scler Relat Disord; 2016 Jan; 5():12-26. PubMed ID: 26856938
[TBL] [Abstract][Full Text] [Related]
8. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.
Biolato M; Bianco A; Lucchini M; Gasbarrini A; Mirabella M; Grieco A
CNS Drugs; 2021 Aug; 35(8):861-880. PubMed ID: 34319570
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
10. Classifying PML risk with disease modifying therapies.
Berger JR
Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
[TBL] [Abstract][Full Text] [Related]
11. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
[TBL] [Abstract][Full Text] [Related]
13. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
14. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
[TBL] [Abstract][Full Text] [Related]
15. Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis.
Porwal MH; Patel D; Maynard M; Obeidat AZ
Mult Scler Relat Disord; 2022 Jul; 63():103832. PubMed ID: 35512502
[TBL] [Abstract][Full Text] [Related]
16. Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
Kingwell E; Zhang T; Zhu F; Walld R; Carruthers R; Evans C; Marrie RA; Tremlett H
Expert Opin Drug Saf; 2021 Apr; 20(4):481-487. PubMed ID: 33342303
[TBL] [Abstract][Full Text] [Related]
17. Laquinimod for multiple sclerosis.
He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
[TBL] [Abstract][Full Text] [Related]
18. "No association between disease modifying treatment and fatigue in multiple sclerosis".
Broch L; Flemmen HØ; Simonsen CS; Berg-Hansen P; Ormstad H; Brunborg C; Celius EG
Mult Scler Relat Disord; 2023 Nov; 79():104993. PubMed ID: 37708819
[TBL] [Abstract][Full Text] [Related]
19. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
